Anal Carcinoma

Treatment

Locally Advanced, 2nd line +

Locally Advanced, 1st/2nd line +

Carcinoembryonic Antigen Negative

VAR0157
Phase 1a/1b
RO7198457 in Combination w/ Atezolizumab in Locally Advanced or Metastatic Tumors
Pi: Fisher
Sponsor: Genentech Inc.

ECOG-ACRIN EA2165
Phase II Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Pi: Fisher

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold